Document:

<PAGE>

                                                                    EXHIBIT 10.2

                        AMENDMENT NO. 1 TO LOAN AGREEMENT

         This Amendment No. 1 to Loan Agreement ("Amendment") is made and
entered into as of December 1, 2000 by and between WILLIAM M. RYCHEL ("RYCHEL")
and TEKGRAF, INC., a Delaware corporation ("TEKGRAF").

         Rychel and Tekgraf are parties to the certain loan agreement dated
December 1, 1999 (the "LOAN Agreement"), a related promissory note dated
December 1, 1999 in the amount of $1,775,000 payable by Rychel to Tekgraf (the
"Promissory Note,") a related collateral assignment dated December 1, 1999 (the
"COLLATERAL ASSIGNMENT") and a related stock pledge agreement dated December 1,
1999 (the "STOCK PLEDGE AGREEMENT").

         Rychel and Tekgraf desire to amend certain of the terms and conditions
of the Loan Agreement as set forth in this Agreement.

         All capitalized terms used but not defined in this Agreement shall have
the meaning set forth in the Loan Agreement.

         NOW, THEREFORE, the parties, intending to legally bound, agree as
follows:

1. Section 1 of the Loan Agreement is amended and restated in its entirety to
read as follows:

         1. THE LOAN. Tekgraf hereby agrees to loan to Rychel, and Rychel hereby
         agrees to, and hereby does, borrow from Tekgraf, in reliance on and
         subject to the terms and conditions contained herein, the amount of
         $1,775,000 (the "LOAN"). The Loan is evidenced by an amended and
         restated promissory note in the form attached to the Amendment No. 1 to
         Loan Agreement as EXHIBIT A, and by this reference incorporated herein
         and made a part hereof (the "NOTE").

2. Section 2 of the Loan Agreement is amended and restated in its entirety to
read as follows:

         2. INTEREST RATE. The outstanding principal balance of the Loan shall
         bear interest at the rate per annum that is one fourth of a percentage
         point (.25%) above the rate paid by Tekgraf from time to time under its
         Amended and Restated Loan and Security Agreement dated as of June 9,
         2000, as amended from time to time, between Tekgraf and Wachovia Bank,
         National Association.

3. Section 3 of the Loan Agreement is amended and restated in its entirety to
read as follows:

<PAGE>

         3. PAYMENT. The principal of and all interest accrued on the Loan shall
         be due and payable on December 1, 2001, or on the next business day if
         December 1, 2001 falls on a day on which national banks are closed.

4. EXHIBIT A to the Loan Agreement is amended and restated in its entirety to
read as set forth on EXHIBIT A to this Amendment.

5. Except as amended by this Amendment, all other provisions of the Loan
Agreement and all provisions of the Share Pledge Agreement and the Collateral
Assignment shall remain in full force and effect as originally written.

         The parties hereto have executed this Amendment to Loan Agreement as of
the day and year first written above.

                                             TEKGRAF, INC.

                                             By:  /s/ Thomas M. Mason
/S/ WILLIAM M. RYCHEL                             ----------------------------
--------------------------------             Its:  CFO
William M. Rychel                                 ----------------------------
980 Corporate Woods Parkway                  980 Corporate Woods Parkway
Vernon Hills, IL 60001                       Vernon Hills, IL 60061
Fax: (954) 697-4329                          Fax: (954) 697-4329

<PAGE>

                          EXHIBIT A TO AMENDMENT NO. 1
                                TO LOAN AGREEMENT

                              AMENDED AND RESTATED
                                 PROMISSORY NOTE

December 1, 2000                                                     $1,775,000

         FOR VALUE RECEIVED, the undersigned (hereafter referred to as the
"MAKER") promises to pay to the order of Tekgraf, Inc. (hereinafter referred to
as "PAYEE") at Payee's address at 980 Corporate Woods Parkway, Vernon Hills, IL
60061 or at such other place as the holder hereof may designate, the principal
sum of One-Million-Seven-Hundred-Seventy-Five-Thousand Dollars ($1,775,000) (the
"LOAN"), together with interest on so much of the principal balance of the Loan
as may be outstanding and unpaid from time to time, calculated on the basis of a
365 day year and actual days elapsed, at the rate per annum that is one fourth
of a percentage point (.25%) above the rate paid by Payee from time to time
under its Amended and Restated Loan and Security Agreement dated as of June 9,
2000, as amended from time to time, between Payee and Wachovia Bank, National
Association (the "INTEREST RATE").

         This Amended and Restated Promissory Note has been given in connection
with the Loan Agreement dated December 1, 1999 as amended by that certain
Amendment No. 1 to Loan Agreement dated December 1, 2000 between Maker and Payee
(the "LOAN AGREEMENT"), and is entitled to all of the benefits of the Loan
Agreement.

         The principal of and accrued interest on the Loan shall be repayable in
a lump sum on December 1, 2001, or on the next business day if December 1, 2001
falls on a day on which national banks are closed. Any overdue payment of
principal or interest on this Amended and Restated Promissory Note shall bear
interest at the Interest Rate plus 5 percentage points, until paid, but only to
the extent that payment of such interest on overdue principal or interest is
enforceable under applicable law.

         Maker may repay this Amended and Restated Promissory Note in whole or
in part at any time without penalty or premium. Each such prepayment shall be
applied first to unpaid interest accrued through the date of such prepayment,
and then to outstanding principal.

         If maker fails to pay within fifteen (15) days after the due date any
amount payable under this Amended and Restated Promissory Note, or if Maker is
otherwise in default under the Loan Agreement, then this Amended and Restated
Promissory Note shall be in default and Payee, at its option, without demand or
further notice of any kind, may declare this Amended and Restated Promissory
Note immediately due and payable, whereupon all outstanding principal and
accrued interest shall become immediately due and payable.

<PAGE>

         In case this Amended and Restated Promissory Note is collected by or
through an attorney-at-law in the event of a default hereunder, all costs of
collection, including reasonable attorney's fees, shall be paid by Maker.

         Time is of the essence.

         This Amended and Restated Promissory Note shall be governed by and
construed in accordance with the laws of the United States of America and the
State of Illinois. Maker irrevocably consents to the exclusive jurisdiction and
venue of the courts of any county in the State of Illinois and the United States
District Court for the Northern District of Illinois, in any judicial proceeding
brought to enforce this Amended and Restated Promissory Note. Maker agrees that
any forum other than the State of Illinois is an inconvenient forum and that a
lawsuit (or non-compulsory counterclaim) brought against Maker in a court of any
jurisdiction other than the State of Illinois should be forthwith dismissed or
transferred to a court located in the State of Illinois.

         This Note is a restatement of the indebtedness evidenced by, and is a
replacement of, that certain Promissory Note of the undersigned dated December
1, 1999 in the face principal amount of $1,775,000 payable to the order of
Payee, and nothing contained herein or in the Amendment No. 1 to the Loan
Agreement dated December 1, 2000 referred to above shall be construed (i) to
deem paid or forgiven the unpaid principal amount of, or unpaid accrued interest
on, said Promissory Note outstanding at the time of its replacement by this
Amended and Restated Promissory Note , or (ii) to release, cancel, terminate or
otherwise adversely affect all or any part of any lien, mortgage, deed of trust,
assignment, pledge, security interest or other encumbrance heretofore granted to
or for the benefit of the payee of said Promissory Note which has not otherwise
been expressly released.

         Words importing the singular number hereunder shall include the plural
number and vice versa, and any pronoun used herein shall be deemed to cover all
genders. Payee shall not be deemed to waive any of its rights unless such waiver
be in writing and signed by Payee. The word "Payee" as used herein shall include
transferees, successors, and assigns of Payee, and all rights of Payee hereunder
shall inure to the benefit of its transferees, successors and assigns. All
obligations of Maker shall bind his heirs, legal representatives and assigns.

         SIGNED, SEALED, AND DELIVERED by the undersigned as of the date first
written above.

                                          [EXHIBIT A - DO NOT SIGN]
                                          William M. Rychel
                                          980 Corporate Woods Parkway
                                          Vernon Hills, IL 60061Prepared by MERRILL CORPORATION www.edgaradvantage.com

QuickLinks
 -- Click here to rapidly navigate through this document
 

Exhibit 10.1

Confidential treatment requested  

   RESEARCH AGREEMENT         

    THIS RESEARCH AGREEMENT dated as of June 8, 1993 (the "Agreement"), is entered into between IXSYS, INC., a Delaware corporation ("Ixsys"), having
a place of business located at 3550 General Atomics Court, Suite L-103, San Diego, California 92121, and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation ("Bristol-Myers"), having a
place of business located at Route 206 and Province Line Road, Princeton, New Jersey 08543-4000. 

WITNESSETH 

    WHEREAS,
Ixsys and Bristol-Myers desire to design and develop products, for use in the in vivo diagnosis or treatment of solid tumors
in humans, through the use of one or more antibodies. 

    WHEREAS,
Bristol-Myers desires to sponsor certain research by Ixsys, and to develop and commercialize, products resulting from such research and development. 

    WHEREAS,
Bristol-Myers and Ixsys are entering into three (3) other agreements, entitled "LICENSE AGREEMENT," "SCREENING AND OPTION AGREEMENT," and "STOCK PURCHASE AGREEMENT,"
dated as of even date herewith, in addition to this "RESEARCH AGREEMENT." 

    NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the parties hereby agree as follows: 

  ARTICLE 1
DEFINITIONS         

    For purposes of the Agreement, the terms defined in this Article 1 shall have the respective meanings set forth below: 

    1.1  "Affiliate"  shall mean, with respect to any Person, any other Person which directly or indirectly
controls, is controlled by, or is under common control with, such Person. A Person shall be regarded as in control of another Person if it owns, or directly or indirectly controls, at least fifty
percent (50%) of the voting stock or other ownership interest of the other Person, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies
of the other Person by any means whatsoever. 

    1.2  "Annual Workplan"  shall mean the research workplan prepared annually in accordance with the
provisions of Section 3.1 below. 

    1.3  "Antibody" and "antibody"  shall mean a molecule
which has the ability to bind an antigen of interest, including without limitation, single chain antibody molecules, Fab fragments, F(ab)2 fragments, Fv fragments, single chain Fv
molecules, and whole antibody molecules. 

    1.4  "BR96 Antibodies"  shall mean those certain Program Antibodies that (a) are murine or
chimeric antibodies and (b) are specifically reactive immunologically with the BR96 antigen, such BR96 antigen having characteristics substantially as described in Exhibit B hereto, as
amended, supplemented or modified from time to time. 

    1.5  "Commencement Date"  shall mean March 21, 1993. 

    1.6  "FDA"  shall mean the United States Food and Drug Administration, or the successor thereto. 

[*]   Confidential treatment requested 

1

    1.7  "Field"  shall mean the in vivo diagnosis or
treatment of solid tumors in humans through the use of one or more antibodies. 

    1.8  "First Commercial Sale"  shall mean, with respect to any Product, the first sale for use or
consumption by the general public of such Product in any country in the Territory after required marketing and pricing approval has been granted, or otherwise permitted, by the governing health
authority of such country. 

    1.9  "Improvements"  shall mean all inventions, discoveries, improvements or other technology, whether or
not patentable, and any patent applications or patents based thereon, made or conceived during and pursuant to the Research Program by employees or others acting solely on behalf of Bristol-Myers or
its Affiliates which represent an improvement to Ixsys' Patent Rights or Ixsys' Know-How. 

    1.10  "Know-How"  shall mean any information and data, which is not generally known
including, but not limited to, formulae, procedures, protocols, techniques and results of experimentation and testing, which are necessary or useful to make, use, develop, sell or seek regulatory
approval in any country in the Territory to market a Product for use in the Field, in which Ixsys or Bristol-Myers has an ownership interest and which is in the possession of Ixsys or Bristol-Myers on
the date of the Agreement or thereafter during the term of the Research Program. 

    1.11  "L6 Antibodies"  shall mean those certain Program Antibodies that (a) are murine or chimeric
antibodies and (b) are specifically reactive immunologically with the L6 antigen, such L6 antigen having characteristics substantially as described in Exhibit B hereto, as amended,
supplemented or modified from time to time. 

    1.12  "License Agreement"  shall mean that certain License Agreement dated as of even date, between Ixsys
and Bristol-Myers, as the same may be amended, modified, supplemented or restated from time to time. 

    1.13  "Net Sales"  shall mean, with respect to any Product, the invoiced sales price of such Product
billed to independent customers who are not Affiliates, less (a) credits, allowances, discounts and rebates to, and chargebacks from the account of, such independent customers for spoiled,
damaged, out-dated or returned Product; (b) actual freight and insurance costs incurred in transporting such Product in final form to such customers; (c) trade discounts,
cash discounts, quantity discounts, rebates and other price reduction programs; (d) sales, value-added and other direct taxes incurred; and (e) customs duties, surcharges and other
governmental charges incurred in connection with the exportation or importation of such Product in final form. 

    1.14  "Patent Rights"  shall mean (a) all patent applications heretofore or hereafter filed or
having legal force in any country within the Territory owned by or licensed to Ixsys or Bristol-Myers or to which Ixsys or Bristol-Myers otherwise acquires rights, which claim a Product or a Program
Antibody or the process of manufacture or use of a Product or a Program Antibody, together with any and all patents that have issued or in the future issue therefrom, including utility, model and
design patents and certificates of invention, and (b) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions or additions to any such
patents and patent applications; all to the extent and only to the extent that Ixsys or Bristol-Myers now has or hereafter will have the right to grant licenses, immunities or other rights thereunder. 

    1.15  "Person"  shall mean an individual, corporation, partnership, trust, business trust, association,
joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 

    1.16  "Prior Agreements"  shall mean the agreement between Ixsys and Bristol-Myers Pharmaceutical
Research Institute and its Affiliates, dated January 23, 1991, as extended by the letter 

2

agreement dated March 16, 1992 and the letter agreement dated August 5, 1992, and the Research and Option Agreement between Bristol-Myers and Ixsys dated September 18, 1992. 

    1.17  "Product"  shall mean any Diagnostic Product or Therapeutic Product. 

    1.17.1  "Diagnostic Product"  shall mean a diagnostic product, containing one or more Program Antibodies,
for use in the in vivo detection of solid tumors in humans. 

    1.17.2  "Therapeutic Product"  shall mean the final dosage formulation of a product incorporating
pharmaceutical compositions containing a Program Antibody for use in the treatment of solid tumors in humans, regardless of the route of administration. Each different chemical formulation of a
Therapeutic Product containing the same one or more Program Antibodies but no additional antibodies, except different formulations for use in the treatment of the same indication in the Field by
different routes of administration, shall constitute a different Therapeutic Product. 

    1.18  "Program Antibody"  shall mean an antibody that (a) is first conceived or synthesized, or
the variable regions of which have been modified, by Ixsys, Bristol-Myers or both during and pursuant to the Research Program; and (b) is specifically reactive immunologically with solid tumor
antigens; whether or not the variable regions of such antibody have been modified by Bristol-Myers, its Affiliates or permitted sublicensees after termination of the Research Program. 

    1.19  "Research Program"  shall mean the research program described in the Annual Worldplans, and the
research performed by Bristol-Myers and Ixsys pursuant to the Prior Agreements. 

    1.20  "Royalty Term"  shall mean, with respect to each Product in each country in the Territory, the
period of time equal to the longer of (a) [*] ([*]) [*] from the date of the First Commercial Sale of such Product in
such country or (b) if the manufacture, use or sale of such Product in such country was at the time of the First Commercial Sale in such country covered by a Valid Patent Claim,
[*]. 

    1.21  "Steering Committee"  shall mean the joint research and development committee composed of
representatives of Ixsys and Bristol-Myers described in Section 5.1 hereof. 

    1.22  "Territory"  shall mean the entire world. 

    1.23  "Third Party"  shall mean any Person other than Ixsys, Bristol-Myers and their respective
Affiliates. 

    1.24  "Valid Patent Claim"  shall mean either (a) a claim of an issued and unexpired patent
included within the Patent Rights, which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable
or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise or (b) a claim of a pending patent
application included within the Patent Rights, which claim was filed in good faith and has not been abandoned or finally disallowed without the possibility of appeal or refiling of such application. 

  ARTICLE 2
REPRESENTATIONS AND WARRANTIES         

    Each party hereby represents and warrants to the other party as follows: 

    2.1  Corporate Existence and Power.  Such party (a) is a corporation duly organized, validly
existing and in good standing under the laws of the state in which it is incorporated and (b) has the corporate power and authority and the legal right to own and operate its property and
assets, to lease the property and assets it operates under lease, and to carry on its business as it is now being conducted. 

3

    2.2  Authorization and Enforcement of Obligations.  Such party (a) has the corporate power and
authority and the legal right to enter into the Agreement and to perform its obligations hereunder and (b) has taken all necessary corporate action on its part to authorize the execution and
delivery of the Agreement and the performance of its obligations hereunder. The Agreement has been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding
obligation, enforceable against such party in accordance with its terms. 

    2.3  Consents.  All necessary consents, approvals and authorizations of all governmental authorities and
other Persons, if any, required to be obtained by such party in connection with the Agreement have been obtained. 

    2.4  No Conflict.  The execution and delivery of the Agreement and the performance of such party's
obligations hereunder (a) do not conflict with or violate any requirement of applicable laws or regulations or any contractual obligation of such party and (b) do not conflict with, or
constitute a default under, any contractual obligation of such party. 

    2.5  DISCLAIMER OF WARRANTIES.  NOTHING IN THE AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE, OR
WARRANTY GIVEN, BY IXSYS OR BRISTOL-MYERS THAT ANY PATENT WILL ISSUE BASED UPON ANY PENDING PATENT APPLICATION WITHIN THE PATENT RIGHTS, THAT ANY PATENT WITHIN THE PATENT RIGHTS WHICH ISSUES WILL BE
VALID, OR THAT THE USE OF ANY LICENSE GRANTED HEREUNDER OR THAT THE USE OF ANY PATENT RIGHTS WILL NOT INFRINGE THE PATENT OR PROPRIETARY RIGHTS OF ANY OTHER PERSON. FURTHERMORE, NEITHER IXSYS NOR
BRISTOL-MYERS MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE PATENT RIGHTS, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE. 

    2.6  Maintenance of Licenses.  Ixsys shall use due diligence to maintain each license agreement between
Ixsys and any Third Party involving Ixsys' Patent Rights sublicensed to Bristol-Myers hereunder. 

  ARTICLE 3
RESEARCH PROGRAM         

    3.1  Annual Workplan.  The Annual Workplan for the period from the Commencement Date through and
including June 30, 1993 is set forth on Exhibit A hereto. The Steering Committee shall prepare and provide to Ixsys and Bristol-Myers on or before July 1, 1993, the Annual
Workplan, in form and substance mutually acceptable to Ixsys and Bristol-Myers, which shall describe the research for the period from July 1, 1993 through and including December 31,
1993. Thereafter, prior to November 1 of each year (commencing on November 1, 1993) during the term of the Research Program, the Steering Committee shall prepare and provide to Ixsys and
Bristol-Myers a proposed Annual Workplan describing the research for the next calendar year. Prior to December 1 of each such year (commencing on December 1, 1993), Ixsys and
Bristol-Myers shall approve such Annual Workplan with such changes as Ixsys and Bristol-Myers muta11y deem necessary. The Annual Workplan shall allocate the responsibilities of the parties to conduct
the research under the Research Program. The Steering Committee may revise the Annual Workplan, from time to time, as approved by the mutual written agreement of Ixsys and Bristol-Myers. 

    3.2  Research Procedures.  

    3.2.1  Conduct of Research.  Ixsys and Bristol-Myers each shall conduct the Research Program in good
scientific manner, and in compliance in all material respects with all requirements of applicable laws, rules and regulations, and all other requirements of any applicable good 

4

laboratory practices to attempt to achieve its objectives efficiently and expeditiously. Ixsys and Bristol-Myers each shall proceed diligently to perform the work set out in the Annual Workplan by
using their respective good faith efforts to provide, among others, the following resources: 

    (a) in
the case of Ixsys, allocation of eight (8) Ixsys scientists per year (measured on a full-time equivalent basis), using personnel with
sufficient skills and experience, together with sufficient equipment and facilities, to carry out its obligations under the Research Program and to accomplish the objectives of the Research Program;
and 

    (b) in
the case of Bristol-Myers, allocation of sufficient time and effort, using personnel with sufficient skills and experience, together with sufficient equipment
and facilities, to carry out its obligations under the Research Program and to accomplish the objectives of the Research Program. 

    3.2.2  Use of Research Funding.  Ixsys shall apply the research funding it receives from Bristol-Myers
under the Agreement to fund the direct and indirect costs of carrying out its obligations under the Research Program and accomplishing the objectives thereof. 

    3.2.3  Exclusivity.  

    (a) During
the term of the Research Program, Ixsys shall not perform any research or development work, with or for the benefit of any Third Party, directed to products
for use in the Field, unless specifically permitted under the Agreement. 

    (b) During
the term of the Research Program, Ixsys shall not engage in any research, development or commercialization of any product, for use in the treatment of cancer
in humans, incorporating pharmaceutical compositions containing one or more antibodies, with or for the benefit of any Third Party, unless Ixsys first offers to Bristol-Myers the right to collaborate
with Ixsys on the research, development and commercialization of such product. Such offer shall specify the material terms and conditions of the offer to be made to Bristol-Myers. If Bristol-Myers
elects to collaborate with Ixsys on the research, development and commercialization of any such product, Bristol-Myers shall deliver to Ixsys written notice of its election within ninety
(90) days after receipt of written notice from Ixsys of Ixsys' intention to collaborate with a Third Party regarding such product. If Bristol-Myers timely exercises its option to collaborate
with Ixsys on the research, development and commercialization of such product, Bristol-Myers and Ixsys shall negotiate in good faith and, within thirty (30) days after receipt of written notice
from Bristol-Myers of its exercise of such option, enter into a collaborative agreement substantially on the terms and conditions offered to Bristol-Myers above. If Bristol-Myers fails to timely
exercise its option to collaborate with Ixsys with respect to any such product or the parties fail to reach agreement after good faith negotiations as provided above, Ixsys shall have the right, in
its sole discretion, to engage in research, development and commercialization of such product with or for the benefit of any Third Party on terms and conditions not materially more favorable to such
Third Party, taken as a whole, than those offered to Bristol-Myers. 

    3.2.4  Subcontracts.  Ixsys and Bristol-Myers each shall have the right to subcontract portions of the
Research Program to be performed by it in the normal course of its business without the prior consent of the other party; provided, however, that
(a) such subcontract shall not involve the transfer of Know-How of the other party to Third Parties; (b) the subcontracted Third Party shall enter into a written
confidentiality agreement with the subcontracting party in accordance with the provisions of Article 12 below; (c) the subcontracting party shall supervise such subcontract work;
(d) the subcontracted Third Party shall be in compliance in all material respects with all requirements of applicable laws and regulations, together with all applicable good laboratory 

5

practices;
and (e) promptly after entering into such subcontract, the subcontracting party shall give written notice thereof to the other party. 

    3.3  Funding of the Research Program.  Upon execution of the Agreement by both parties, Bristol-Myers
shall pay Ixsys the sum of $[*] in support of research by Ixsys under the Research Program for one year following the Commencement Date. Thereafter, on or before each
anniversary of the Commencement Date during the remaining term of the Research Program, Bristol-Myers shall pay Ixsys a research fee
equal to the [*]. If Bristol-Myers and Ixsys mutually agree to increase the scope of the Research Program, then Bristol-Myers shall pay Ixsys an additional annual fee to be
agreed upon by the parties. 

    3.4  Records and Reports.  

    3.4.1  Records.  Ixsys and Bristol-Myers each shall maintain records, in sufficient detail and in good
scientific manner, which shall be complete and accurate and shall fully and properly reflect all work done and results achieved in the performance of the Research Program (including all data in the
form required under all applicable laws and regulations). 

    3.4.2  Inspection of Records.  Ixsys and Bristol-Myers each shall have the right, during normal business
hours and upon reasonable notice, to inspect and copy all such records of the other party to the extent reasonably required for the performance of its obligations under the Agreement (with the party
owning the records determining what is reasonably required). Each party shall maintain such records and the information of the other party contained therein in confidence in accordance with
Section 12.1 below and shall not use such records or information except to the extent otherwise permitted by the Agreement. 

    3.4.3  Research Reports and Information.  Ixsys and Bristol-Myers each shall keep the other informed of
the progress of such party under the Research Program. Within thirty (30) days following each April 30, August 31 and December 31 during the term of the Research Program
and within thirty (30) days following the expiration or termination of the Research Program, Ixsys and Bristol-Myers each shall prepare, and distribute to each member of the Steering Committee
and the other party, a reasonably detailed written summary report which shall describe the work performed by such party to date under the Research Program. 

    3.5  Term of Research Program.  Subject to the provisions of Section 15.2 below, the term of the
Research Program shall continue for a period of [*] ([*]) [*] after the Commencement Date; provided,
however, the term of the Research Program may be extended for an additional period of [*] ([*]) [*], by
the mutual written agreement of the parties not less than [*] ([*]) [*] prior to the [*] anniversary of
the Commencement Date. 

    3.6  Project Leaders.  Ixsys and Bristol-Myers each shall appoint a person (a "Project Leader") to
coordinate its activities under the Research Program. The Project Leaders shall be the primary contacts between the parties with respect to the Research Program. Each party shall notify the other
within
thirty (30) days after the date of the Agreement of the appointment of its Project Leader and shall notify the other party as soon practicable upon changing this appointment. 

    3.7  Material Transfer.  In order to facilitate the Research Program, either party may provide to the
other party certain biological materials or chemical compounds including, but not limited to, structural genes, genetic sequences, promoters, enhancers, probes, linkage probes, vectors, hosts,
plasmids, peptides, polypeptides, transgenic animals, proteins, biological modifiers, antigens, hybridomas, antibodies, toxins, lectins, enzymes, lipids, hormones, viruses, viroids, cell or parts of
cells, cell lines and transformed cell lines, and any progeny, replicates, mutants, fragments and derivatives of the foregoing (collectively, "Material') owned by or licensed to the supplying party
(other than under the Agreement) for use by the other party in furtherance of the Research Program. Except as otherwise 

6

provided under the Agreement, all such Material delivered to the other party (a) shall remain the sole property of the supplying party, (b) shall be used only in furtherance of the
Research Program and solely under the control of the other party, (c) shall not be used or delivered to or for the benefit of any Third Party without the prior written consent of the supplying
party, and (d) shall not be used in research or testing involving human subjects. The Materials supplied under this Section 3.7 must be used with prudence and appropriate caution in any
experimental work, since not all their characteristics may be known. THE MATERIALS ARE PROVIDED AS IS AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY
IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIAL WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY
THIRD PARTY. 

  ARTICLE 4
DEVELOPMENT AND COMMERCIALIZATION         

    4.1  Preclinical and Clinical Development.  The decision as to whether to proceed with the preclinical
and clinical development and marketing of any Product shall be in the sole discretion of Bristol-Myers. Nothing contained in this Agreement shall be interpreted as requiring Bristol-Myers to develop
or market any Product. Bristol-Myers shall comply with all applicable laws and regulations and good
laboratory, clinical and manufacturing practices in the preclinical and clinical development of the Products which Bristol-Myers elects to develop, and shall cause its Affiliates and subcontractors to
do the same. 

    4.2  Development Reports and Information.  Bristol-Myers shall keep Ixsys informed as to the progress of
the preclinical and clinical development and testing of all Products which Bristol-Myers elects to develop and the preparing, filing and obtaining of the approvals necessary for marketing of all
Products. Within thirty (30) days following each April 30, August 31 and December 31 following the commencement of preclinical development of a Product undertaken by
Bristol-Myers, Bristol-Myers shall provide to Ixsys a written report which shall summarize the progress of the development and testing of Products in preclinical development and clinical trials. In
addition, Bristol-Myers shall provide to Ixsys a minimum of six (6) months advance written notice of the contemplated filing of an Investigational New Drug application ("IND") with the FDA in
the United States (or its equivalent in any other country), a written report which shall summarize all other regulatory submissions prior to the date of such submissions, and written notice of all
approvals obtained promptly after obtaining such approvals. 

  ARTICLE 5
MANAGEMENT OF THE RESEARCH PROGRAM         

    5.1  Steering Committee.  

    5.1.1  Composition of the Steering Committee.  The Research Program shall be conducted under the
direction of the Steering Committee comprised of three (3) named representatives of Ixsys and three (3) named representatives of Bristol-Myers. Each party shall appoint its respective
representatives to the Steering Committee from time to time, and may substitute one or more of its representatives, in its sole discretion, effective upon notice to the other party of such change.
Members of the Steering Committee may be represented at any meeting by another member of the Steering Committee, or by a deputy. 

    5.1.2  Meetings.  The Steering Committee shall meet not less than once every four months during the term
of the Agreement, on such dates and at such times and places as agreed to by 

7

Ixsys and Bristol-Myers, alternating between San Diego and Princeton, or such other locations as the parties shall agree. At such meetings, the Steering Committee shall discuss the Research Program
and set priorities therefor. 

    5.1.3  Committee Actions.  Any approval, determination or other action agreed to by all of the members of
the Steering Committee or their deputies present at the relevant Steering Committee meeting shall be the approval, determination or other action of the Steering Committee;  provided, however, that at
least two (2) representatives of each party are present at such meeting. 

    5.2  Disagreements.  All disagreements within the Steering Committee shall be resolved in the following
manner: 

    5.2.1  The
representatives of the Steering Committee promptly shall present the disagreement to the executive of each of Ixsys and Bristol-Myers who has
the principal responsibility for such party's work under the Agreement. 

    5.2.2  Such
executives shall meet to discuss each party's view and to explain the basis for their respective positions of such disagreement, and in good
faith shall attempt to resolve such disagreement among themselves. 

    5.2.3  If
such executives cannot promptly resolve such disagreement, then such executives shall establish a mechanism to resolve such disagreement
promptly; provided, however, that the parties do not waive any rights which they may have under the Agreement or otherwise as a result of one party's
settlement of a disagreement under this Section 5.2.3. 

    5.3  Steering Committee Reports.  Within thirty (30) days following each Steering Committee
meeting during the term of the Agreement, the Steering Committee shall prepare, and distribute to each party, a reasonably detailed written summary report which shall (a) describe the work
performed to date on the Research Program and (b) evaluate the work performed in relation to the goals of the Research Program. 

    5.4  Availability of Employees.  Each party shall make its employees and relevant reports of
non-employee consultants available, upon reasonable notice during normal business hours, at their respective places of employment to consult with the other party on issues arising during
the Research Program and in connection with any request from any regulatory agency. 

    5.5  Visit of Facilities.  Representatives of Ixsys and Bristol-Myers may, upon reasonable notice during
normal business hours, (a) visit the facilities where the Research Program is being conducted, (b) consult informally, during such visits and by telephone, with personnel of the other
party performing work on the Research Program and (c) with the other party's prior approval, which approval shall not be withheld unreasonably, visit the sites of any other experiments being
conducted by such other party in connection with the Research Program but only to the extent in each case as such other experiments relate to the Research Program. On such visits an employee of the
party conducting the research shall accompany the employee(s) of the visiting party. 

  ARTICLE 6
GRANT OF LICENSES         

    6.1  License Grant to Bristol-Myers.  

    6.1.1  License to Make, Have Made, Use and Sell.  Except as otherwise provided in the Agreement, Ixsys
hereby grants to Bristol-Myers an exclusive license (or in the case of licensed Third Party Patent Rights, when permissible, an exclusive sublicense) in the Territory under Ixsys' Patent Rights,
including Ixsys' rights in any jointly-owned Patent Rights, and Ixsys Know-How, to 

8

make, have made, use and sell Products in the Field. Bristol-Myers may not grant sublicenses under such license without-the prior written consent of Ixsys, except sublicenses (without the
right to grant further sublicenses) solely for the purpose of (a) subcontract manufacturing and supplying Program Antibodies or Products to Bristol-Myers and its permitted sublicensees, and
(b) after receipt of the required marketing approval from the FDA to sell a Product, the making, using, promoting, marketing and selling of such Product for use in the Field. Each permitted
sublicense shall be subject to the terms and conditions of the Agreement. Bristol-Myers shall deliver a copy of each permitted sublicense under the Agreement to Ixsys within ten (10) business
days after execution of the same. 

    6.1.2  Restrictions upon Use of Ixsys' Technology.  Except as otherwise authorized by the prior written
consent of Ixsys or as expressly permitted in the License Agreement, Bristol-Myers shall not, directly or indirectly, (a) use any of Ixsys' Patent Rights or Ixsys' Know-How to
modify the variable regions of any Program Antibody after the term of the Research Program, (b) use Ixsys' Patent Rights or Ixsys' Know-How other than to make, have made, use or
sell Products for use in the Field, (c) sell, assign, transfer, encumber or otherwise dispose of Ixsys' Patent Rights or Ixsys' Know-How, or (d) authorize, cause or assist
any other Person in any of the foregoing matters. 

    6.1.3  Reservation of Rights in Ixsys.  Subject to the provisions of Section 3.2.3(a) above and
Section 6.3 below, and except as otherwise provided in the Agreement, Ixsys reserves the exclusive right under Ixsys Patent Rights, including Ixsys' rights in any jointly-owned Patent Rights,
and Ixsys' Know-How, to make, have made, use and sell products for all purposes in all fields and territories and at all times not expressly licensed to Bristol-Myers under
Section 6.1.1 above. If Ixsys, its Affiliates or sublicensees commercialize a product, containing one or more Program Antibodies, for use in the in
vitro diagnosis of solid tumors in humans, the parties shall negotiate in good faith a reasonable royalty, not to exceed [*] percent
([*]%) of net sales of such product, payable by Ixsys to Bristol-Myers on sales of such product. 

    6.1.4  Product Use Outside the Field.  Upon written request by Bristol-Myers, to the extent legally and
contractually permitted, the parties shall meet and negotiate in good faith a license from Ixsys to Bristol-Myers in the Territory, under Ixsys' Patent Rights, including Ixsys' rights in any
jointly-owned Patent Rights, and Ixsys' Know-How, to make, use and sell a Product for such use outside the Field as the parties mutually agree on such terms and conditions as the parties
mutually agree. 

    6.2  License Grant to Ixsys.  Subject to the provisions of Section 6.3 below, Bristol-Myers hereby
grants to Ixsys a nonexclusive, irrevocable, royalty-free, worldwide license, including the right to grant sublicenses, under Bristol-Myers' rights in the Improvements to make, use and
sell products which employ, incorporate or are produced using the Improvements for all-purposes in all fields, other than to make, use or sell a Product in the Territory for use in the
Field. Within thirty (30) days following each April 30, August 31 and December 31 during the term of the Agreement, Bristol-Myers shall provide Ixsys with written reports
of information regarding Improvements as it becomes available to Bristol-Myers. 

    6.3  Restrictions Upon Ixsys' Use of Program Antibodies.  Notwithstanding anything to the contrary in the
Agreement, Ixsys shall not, whether within or outside the Field and whether itself or with or by any Affiliate or Third Party, make, use, sell, develop or commercialize (a) any Program
Antibody, Product or related Material necessary solely for the production or use of any Program Antibody or Product or any use of any Program Antibody or Product, or any Patent Rights which claim
solely any of the foregoing, or (b) Improvements to any Program Antibody, Product or related Material necessary solely
for the production or use of any Program Antibody or Product, or any Patent Rights which claim solely any of the foregoing or any use of any Program Antibody or Product, except for the purpose of
satisfying its obligations under the Research Program; provided, however, that Ixsys shall have the right, 

9

itself or with any Affiliate or Third Party, to use, develop or commercialize any Program Antibody or Product ([*] or Improvements to the foregoing or Patent Rights which claim
solely any of the foregoing) for use in the in vitro diagnosis of [*], in accordance with the royalty provisions of
Section 6.1.3 above. 

  ROYALTIES AND MILESTONE PAYMENTS         

    7.1  Royalties.  In consideration for Ixsys participation in the Research Program and for the licenses
granted to Bristol-Myers herein, during the Royalty Term, Bristol-Myers shall pay to Ixsys royalties equal to (a) [*] percent ([*]%) of Net Sales
of all Products by Bristol-Myers, its Affiliates and permitted sublicensees in the Territory, except for Products containing BR96 Antibodies or L6 Antibodies (and no other Program Antibodies), and
(b) [*] percent ([*]%) of Net Sales of all Products containing BR96 Antibodies or L6 Antibodies (and no other Program Antibodies) by
Bristol-Myers, its Affiliates and permitted sublicensees in the Territory. 

    7.2  Third Party Royalties.  Bristol-Myers, at its sole expense, shall pay all royalties owing to any
Third Party in order to exercise Bristol-Myers' rights hereunder to make, use or sell any Product. If the aggregate royalties owing by Bristol-Myers to Third Parties in order to exercise
Bristol-Myers' rights hereunder to make, use or sell a Product exceed [*] percent ([*]%) of Net Sales of such Product, Bristol-Myers shall negotiate in
good faith with Ixsys and all such Third Parties mutually acceptable, appropriate and equitable adjustments, if any, to the royalties owing to Ixsys and each Third Party with respect to such Product
as necessary to make the commercialization of such Product commercially feasible; provided, however, that in no event shall the royalty owing to Ixsys
under Section 7.1(a) above be reduced to less than [*] percent ([*]%) of Net Sales with respect to such Product, and under Section 7.1(b)
above be reduced to less than [*] percent ([*]%) of Net Sales with respect to such Product. 

    7.3  Combination Product.  Notwithstanding the foregoing, in the event a Product contains, in addition to
Program Antibodies, one or more other biologically active components to produce a combination product, Net Sales, for purposes of royalty payments on the combination product, shall be calculated by
multiplying the Net Sales of that combination product by the fraction A/B, where A is the gross selling price of the Program Antibodies sold separately and B is the gross selling price of the
combination
product. If no such separate sales are made by Bristol-Myers, its Affiliates or permitted sublicensees, Net Sales for royalty determination shall be calculated by multiplying Net Sales of the
combination by the fraction C/(C+D), where C is the fully allocated cost of the combination product (excluding the fully allocated cost of the other biologically active components in question) and D
is the fully allocated cost of such other biologically active components. In no event shall the royalty owing to Ixsys under Section 7.1(a) above be reduced to less than
[*] percent ([*]%) of Net Sales with respect to such Product, and under Section 7.1(b) above be reduced to less than [*]
percent ([*]%) of Net Sales with respect to such Product. 

    7.4  Milestone Payments.  As partial consideration for the research performed by Ixsys under the Research
Program as set forth in the Agreement, Bristol-Myers shall pay Ixsys the following milestone payments upon the first occurrence of each event set forth below with respect to each Product: 

    7.4.1  $[*]
upon filing with the FDA an IND in the United States (or its equivalent in any other country); and 

    7.4.2  $[*]
upon commencement of Phase 2/3 (pivotal) clinical trials, or Phase 3 clinical trials, in the United States
(or their equivalent in any other country); and 

    7.4.3  $[*]
upon filing a New Drug Application ("NDA") in the United States (or its equivalent in any other country); and 

10

    7.4.4  $[*] upon receipt of the required marketing and pricing approval from the FDA (or from the governing health authority of
any other country). 

    7.5  Single Royalty.  Notwithstanding anything to the contrary in the Agreement, only one royalty shall
be due to Ixsys with respect to each Product sold by Bristol-Myers, its Affiliates and permitted sublicensees hereunder regardless of the number of issued patents owned and licensed by Ixsys, if any,
which would be infringed by making, using, or selling such Product absent the licenses granted to Bristol-Myers under the Agreement and any other agreements with Ixsys, including without limitation
the License Agreement and whether pursuant to the Agreement or any other agreement with Ixsys, including without limitation the License Agreement; provided,
however, that the royalty owing to Ixsys
with respect to each Product shall be the highest royalty applicable to such Product under the Agreement and any other such agreement with Ixsys. 

  ARTICLE 8
ROYALTY REPORTS AND ACCOUNTING         

    8.1  Reports, Exchange Rates.  During the term of the Agreement following the First Commercial Sale of a
Product, Bristol-Myers shall furnish to Ixsys a quarterly written report showing in reasonably specific detail, on a country by country basis, (a) the gross sales of all Products sold by
Bristol-Myers, its Affiliates and its sublicensees in the Territory during the reporting period and the calculation of Net Sales from such gross sales; (b) the royalties payable in United
States dollars, if any, which shall have accrued hereunder based upon Net Sales of Products; (c) the withholding taxes, if any, required by law to be deducted in respect of such sales
(d) the date of the First Commercial Sales of each Product in each country in the Territory during the reporting period; and (e) the exchange rates used in determining the amount of
United States dollars. With respect to sales of Products invoiced in United States dollars, the gross sales, Net Sales, and royalties payable shall be expressed in United States dollars. With respect
to sales of Products invoiced in a currency other than United States dollars, the gross sales, Net Sales and royalties payable shall be expressed in the domestic currency of the party making the sale
together with the United States dollar equivalent of the royalty payable, calculated using the average buying rate for such currency quoted in the continental terms method of quoting exchange rates
(local currency per US$1) by as published in the United States in The Wall Street Journal under the caption "Currency Trading" on each of the last
business day of each month in the quarter prior to the date of payment. Reports shall be due on the sixtieth (60th) day following the close of each quarter. Bristol-Myers shall keep complete and
accurate records in sufficient detail to properly reflect all gross sales and Net Sales and to enable the royalties payable hereunder to be determined. 

    8.2  Audits.  

    8.2.1  Upon
the written request of Ixsys and not more than twice in each calendar year, Bristol-Myers shall permit an independent certified public
accounting firm of nationally recognized standing, mutually acceptable to Ixsys and Bristol-Myers, at Ixsys' expense, to have access during normal business hours to such of the records of
Bristol-Myers solely to the extent necessary to verify the accuracy of the royalty reports hereunder for any year ending not more than twenty-four (24) months prior to the date of
such request. The accounting firm shall disclose to Ixsys only whether the records are correct or not and the specific details concerning any discrepancies. No other information or details of the
audit shall be disclosed to Ixsys. 

    8.2.2  If
such accounting firm concludes that additional royalties were owed during such period, Bristol-Myers shall pay the additional royalties within
thirty (30) days of the date Ixsys delivers to Bristol-Myers such accounting firm's written report so concluding. The fees charged by such accounting firm shall be paid by Ixsys;  provided, however,
if the audit discloses that the royalties payable by Bristol-Myers for the audited period are more than one hundred eight percent 

11

(108%) of the royalties actually paid for such period, then Bristol-Myers shall pay the reasonable fees and expenses charged by such accounting firm. 

    8.2.3  Bristol-Myers
shall include in each permitted sublicense granted by it pursuant to the Agreement a provision requiring the sublicensee to make
reports to Bristol-Myers, to keep and maintain records of sales made pursuant to such sublicense and to grant access to such records by Ixsys' independent accountant to the same extent required of
Bristol-Myers under the Agreement. Upon the expiration of twenty-four (24) months following the end of any year, the calculation of royalties payable with respect to such year shall
be binding and conclusive upon Ixsys and Bristol-Myers, its Affiliates and permitted sublicensees shall be released from any liability or accountability with respect to royalties for such year. 

    8.3  Confidential Financial Information.  Ixsys shall treat all financial information subject to review
under this Article 8 or under any sublicense agreement as the confidential information of Bristol-Myers, and shall cause its accounting firm to retain all such financial information in
confidence. 

  ARTICLE 9
PAYMENTS         

    9.1  Payment Terms.  Royalties shown to have accrued by each royalty report provided for under
Article 8 of the Agreement shall be due and payable on the date such royalty report is due. Payment of royalties in whole or in part may be made in advance of such due date. 

    9.2  Payment Method.  Except as provided in this Section 9.2, all payments by Bristol-Myers to
Ixsys under the Agreement shall be paid in United States dollars, and all such payments shall be originated from a United States bank located in the United States and made by bank wire transfer in
immediately available funds to such account as Ixsys shall designate before such payment is due. 

    9.3.  Exchange Control.  If at any time legal restrictions prevent the prompt remittance of part or all
royalties with respect to any country in the Territory where the Product is sold, payment shall be made through such lawful means or methods as Bristol-Myers reasonably determines and to which Ixsys
consents, which consent shall not be unreasonably withheld. 

    9.4  Withholding Taxes.  All amounts owing from Bristol-Myers to Ixsys under the Agreement are net
amounts, and shall be grossed-up to account for any withholding taxes, value-added taxes or other taxes, levies or charges with respect to such amounts, other than United States taxes,
payable by Bristol-Myers, its Affiliates or sublicensees, or any taxes required to be withheld by Bristol-Myers, its Affiliates or sublicensees to the extent such taxes are imposed by reason of
Bristol-Myers, its Affiliates or sublicensees having a permanent establishment in any country within the Territory or otherwise being subject to taxation by such country (except solely by reason of
the license granted under the Agreement). 

    9.5  Late Payments.  Unless otherwise provided in the Agreement, Bristol-Myers shall pay interest to
Ixsys on the aggregate amount of any payments by Bristol-Myers that are not paid on or before the date such payments are due under the Agreement at a rate per annum equal to the lesser of the prime
rate of interest as published in the United States in The Wall Street Journal under the caption "Money Rates," from time to time, plus two percent (2%),
or the highest rate permitted by applicable law, calculated on the number of days such payment is delinquent. 

12

  ARTICLE 10
[INTENTIONALLY OMITTED]         

  ARTICLE 11
INFRINGEMENT ACTIONS BY THIRD PARTIES         

    11.1  Notice of Suit or Claim of Infringement.  Each party shall promptly notify the other in writing in
the event that either party, or, in the case of Bristol-Myers, its permitted sublicensees or customers, are notified by a Third Party of infringement of a patent, or are sued by a Third Party for
infringement of a patent, on account of the manufacture, use or sale of any Program Antibody or Product. 

    11.2  Control of Defense.  

      11.2.1(a)
Except as provided in subparagraphs (b) and (c) of this Article 11.2.1 and in Article 11.2.2, Ixsys shall have
the right, in its sole discretion, and at its sole expense, to control the defense of any suit brought by a Third Party, alleging that the manufacture, use or sale of any Program Antibody or Product
or the use of any process to make a Program Antibody or Product infringes a patent, where such products or processes are claimed under the Ixsys patents and patent applications listed in
Schedule C as such schedule may be amended, supplemented or modified from time to time by Ixsys with the written consent of Bristol-Myers which shall not be unreasonably withheld. In such
event, Bristol-Myers shall have the right to be represented by advisory counsel of its own selection, at its own expense, and shall cooperate fully in the defense of such suit and furnish to Ixsys all
evidence and assistance in its control. 

    (b)
Bristol-Myers shall have the right, in its sole discretion and at its sole expense, to control the defense of any suit brought by a Third Party
described in subparagraph (a) above in the event that Bristol-Myers notifies Ixsys in writing before institution of such Third Party suit that the relevant Program Antibody or Product has
entered preclinical development, as evidenced by the approval of a Preclinical Lead Profile or equivalent document by the management of the Bristol-Myers Squibb Pharmaceutical Group. In such event,
Ixsys shall have the right to be represented by advisory counsel of its own selection, at its own expense, and shall cooperate fully in the defense of such suit and furnish to Bristol-Myers all
evidence and assistance in its control. 

    (c)
Bristol-Myers shall have the right to gain control from Ixsys of the defense of any Third Party suit initially controlled by Ixsys pursuant to
Section 11.2.1(a) above, in the event that Bristol-Myers notifies Ixsys in writing, after institution of such Third Party suit, that the relevant Program Antibody or
Product has entered preclinical development, as evidenced by the approval of a Preclinical Lead Profile or equivalent document by the management of the Bristol-Myers Squibb Pharmaceutical Group;  provided, however,
 that Bristol-Myers shall reimburse Ixsys, on demand, for all expenses incurred by Ixsys in the defense of such Third Party suit prior
to Bristol-Myers assuming control thereof. In such event, Bristol-Myers shall have the right, in its sole discretion and at its sole expense, to control the defense of such Third Party suit, and Ixsys
shall have the right to be represented by advisory counsel of its own selection, at its own expense, and shall cooperate fully in the defense of such suit and furnish to Bristol-Myers all evidence and
assistance in its control. 

      11.2.2  Bristol-Myers
shall have the right, in its sole discretion and at its sole expense, to control the defense of all other suits
under this Article 11. In such event, Ixsys shall have the right to be represented by advisory counsel of its own selection, at its own expense, and shall cooperate fully in the defense of such
suit and furnish to Bristol-Myers all evidence and assistance in its control. 

13

      11.2.3  If the party having the right to control the defense of such suit (the "Electing Party") does not elect to control the defense
of such suit in writing within thirty (30) days after having been notified or sued, as the case may be, by the Third Party, the other party may elect in writing to undertake such control at its
own expense; provided, however, that the Electing Party shall then have the right to be represented by the advisory counsel of its own selection and at
its own expense, and the Electing Party shall cooperate fully in the defense of such suit and furnish to the other party all evidence and assistance in the Electing Party's control;  provided, further,
that if Ixsys is the Electing Party pursuant to Section 11.2.1(a) above with respect to any suit and is subsequently notified
by Bristol-Myers pursuant to Section 11.2.1(c) above that Bristol-Myers has elected to control the defense of such suit, then Bristol-Myers shall become the Electing Party with respect to such
suit. 

      11.2.4  The
party controlling the defense of any suit under this Article 11 shall vigorously defend such suit and assert all
reasonable defenses which may be asserted in good faith, and shall keep the non-controlling party advised at all times of all aspects of such suit, including the defense and settlement
thereof; provided, however, that nothing in this Section 11.2.4 shall prohibit the party controlling the defense of such suit from entering into
settlement negotiations and settling such suit on the terms and subject to the conditions of the Agreement. 

    11.3  Settlement.  The party controlling the defense of the suit may not settle the suit or consent to an
adverse judgment in such suit in a manner that, in either event, results in a judicial admission that the Third Party patent which is the subject of the suit dominates the Patent Rights of the
non-controlling party, without the express written consent of the non-controlling party, which shall not be unreasonably
withheld. The party settling such suit shall provide the other party fifteen (15) days prior written notification of the details of any settlement before settling such suit. Any judgments,
settlements or damages payable with respect to legal proceedings covered by this Article 11 shall be paid by the party which controls the litigation. 

  ARTICLE 12
CONFIDENTIALITY         

    12.1  Nondisclosure Obligations.  Except as otherwise provided in this Article 12 and
Article 13, (a) during the term of the Agreement and for a period of seven (7) years thereafter, both parties shall maintain in confidence and use only for purposes of the
Agreement information and data resulting from the development of Program Antibodies or Products pursuant to the Research Program; (b) during the term of the Agreement and for a period of seven
(7) years thereafter, both parties shall maintain in confidence and use only for purposes of the Agreement information and data not described in clause (a) above resulting from the
Research Program; and (c) during the term of the Agreement and for a period of seven (7) years thereafter, both parties shall also maintain in confidence and use only for purposes of the
Agreement all information and data not described in clause (a) or (b) above but supplied by the other party under the Agreement marked "Confidential." For purposes of this
Article 12 and Article 13, information and data described in clause (a), (b) or (c) above shall be referred to as "Information." 

    12.2  Permitted Disclosures.  To the extent it is reasonably necessary or appropriate to fulfill its
obligations or exercise its rights under the Agreement, (a) a party may disclose Information it is otherwise obligated under this Article 12 not to disclose to its Affiliates,
sublicensees, consultants, outside contractors and clinical investigators, on a need-to-know basis on condition that such Persons agree to keep the Information confidential for
the same time periods and to the same extent as such party is required to keep the Information confidential; and (b) a party or its sublicensees may disclose such Information to government or
other regulatory authorities to the extent that such disclosure is required by applicable law, regulation or court order, or is reasonably necessary to obtain patents or 

14

authorizations to conduct clinical trials with, and to commercially market the Product, provided that such party shall provide written notice to the other party and sufficient opportunity to the other
party to object to such disclosure or to request confidential treatment thereof. 

    The
obligation not to disclose or use Information shall not apply to any part of such Information that (i) is or becomes patented, published or otherwise part of the public
domain other than by acts of the party obligated not to disclose such Information or its Affiliates or sublicensees in contravention of the Agreement; (ii) is disclosed to the receiving party
or its Affiliates or sublicensees by a Third Party, provided such Information was not obtained by such Third Party directly or indirectly from the other party under the Agreement on a confidential
basis; (iii) prior to disclosure under the Agreement, was already in the possession of the receiving party or its Affiliates or sublicensees, provided such Information was not obtained directly
or indirectly from the other party under the Agreement; (iv) is disclosed in a press release agreed to by both parties hereto, which agreement shall not be unreasonably withheld; or
(v) is independently developed by or for the receiving party or its Affiliates or permitted sublicensees by persons who did not have access to Information disclosed by the other party under the
Agreement. 

    12.3  Terms of the Agreement.  Ixsys and Bristol-Myers shall not disclose any terms or conditions of the
Agreement to any Third Party without the prior consent of the other party, except as required by applicable law or to Persons with whom Bristol-Myers or Ixsys has entered into or proposes to enter
into a business relationship, provided that such Persons shall enter into the required confidentiality agreement. Notwithstanding the foregoing, prior to execution of the Agreement, Bristol-Myers and
Ixsys shall agree upon the substance of information that can be used to describe the terms of this transaction, and Bristol-Myers and Ixsys may disclose such information, as modified by mutual
agreement from time to time, without the other party's consent. 

  ARTICLE 13
PUBLICATION         

    13.1  Notice of Publication.  During the term of the Agreement, Ixsys and Bristol-Myers each acknowledge
the other party's interest in publishing certain of its results to obtain recognition within the scientific community and to advance the state of scientific knowledge. Each party also recognizes the
mutual interest in obtaining valid patent protection and protecting business interests. Consequently, either party, its employees or consultants wishing to make a publication (including any oral
disclosure made without obligation of confidentiality) relating to work performed by such party as part of the Research Program (the "Publishing Party") shall transmit to the other party (the
"Reviewing Party") a copy of the proposed written publication at least forty-five (45) days prior to submission for publication, or an outline of such oral disclosure at least
forty-five (45) days prior to presentation. The Reviewing Party shall have the right (a) to propose modifications to the publication for patent reasons, (b) to request
a reasonable delay in publication in order to protect patentable information and (c) to edit the publication in a manner reasonably acceptable to the Publishing Party to protect its
Information. 

    13.2  Timing of Publication.  If the Reviewing Party requests such a delay, the Publishing Party shall
delay submission or presentation of the publication for a period of ninety (90) days to enable patent applications protecting each party's rights in such information to be filed in accordance
with Article 14 below. Upon the expiry of forty-five (45) days from transmission to the Reviewing Party, the Publishing Party shall be free to proceed with the written
publication or the presentation, respectively, unless the Reviewing Party has requested the delay described above. 

    13.3  Prohibited Publications.  Notwithstanding anything to the contrary in the Agreement, neither party
shall publish or otherwise disclose to any Third Party any Information of the other party without the prior written consent of the other party. 

15

  ARTICLE 14
PATENTS         

    14.1  Ownership of Inventions, Applications for Patent and Patents.  Except as otherwise provided in the
Agreement, the entire right and title in all inventions, discoveries, improvements or other technology, including without limitation inventions, improvements or other technology directed to a Product
or Program Antibody or the manufacture or use of a Product or Program Antibody, and all processes relating thereto, whether or not patentable, and any patent applications or patents based thereon,
made or conceived during and pursuant to the Research Program (collectively, the "Inventions") (a) solely by employees or others acting on behalf of Ixsys or its Affiliates shall be owned
solely by Ixsys (the "Ixsys Inventions"), (b) solely by employees or others acting on behalf of Bristol-Myers or its Affiliates shall be owned solely by Bristol-Myers (the "Bristol-Myers
Inventions"), and (c) jointly by employees or others acting on behalf of Ixsys and Bristol-Myers, or their respective Affiliates, shall be owned jointly by Ixsys and Bristol-Myers (the "Joint
Inventions"). Each party promptly shall disclose to the other party the making, conception or reduction to practice of Inventions by employees or others acting on behalf of such party. Ixsys and
Bristol-Myers each hereby represents that all employees and other Persons acting on its behalf in performing its Obligations under the Agreement shall be obligated under a binding written agreement to
assign to it, or as it shall direct, all Inventions made or developed by such employees or other Persons. Inventorship and ownership determinations for all Inventions, whether patentable or not, shall
be made in accordance with United States patent laws. 

    14.2  Patent Applications.  

    14.2.1  Priority Filings.  When an Invention has been made which may reasonably be considered to be
patentable, (a) Bristol-Myers in the case of (i) all Bristol-Myers Inventions, (ii) those Joint Inventions that constitute composition of matter and related use inventions
(including without limitation Joint Inventions that constitute Program Antibodies, Products or related Materials necessary solely for the production or use of Program Antibodies or Products or the use
of Program Antibodies or Products), and (iii) those Ixsys Inventions that constitute BR96 Antibodies, human or humanized BR96 antibodies, L6 Antibodies, human or humanized L6 antibodies or
Products containing BR96 Antibodies, human or humanized BR96 antibodies, L6 Antibodies, human or humanized L6 antibodies, or related Materials necessary solely for the production or use of any of the
foregoing or the use of Program Antibodies or Products, and (b) Ixsys in the case of all other Joint Inventions and all other Ixsys Inventions, shall file a priority patent application
in the United States as soon as reasonably practicable. The party filing the application shall give the other party an opportunity to review the text of the application before filing, shall control
the preparation and filing of such application, and shall supply the other party with a copy of the application as filed, together with notice of its filing date and serial number. 

    14.2.2  Foreign Filing Decisions.  No later than nine (9) months following the filing date of a
priority patent application filed according to Section 14.2.1 above, the parties shall consult together, through the Steering Committee or otherwise, to determine whether such priority patent
application should be abandoned without replacement; abandoned and refiled; proceeded within the country of filing only; or used as the basis for a claim of priority under the Paris Convention for
corresponding applications in other countries. The parties shall consult together to ensure that so far as practicable the texts filed in the United States and in other countries contain the same
information and claim the same scope of protection. 

    14.2.3  Prosecution and Maintenance.  Ixsys and Bristol-Myers each shall have the right, using
commercially reasonable practices, to control the prosecution, grant and maintenance of its Patent Rights, and to select all patent counsel or other professionals to advise, represent or act 

16

for it in all matters relating to its Patent Rights, except as otherwise provided in this Article 14. Bristol-Myers shall control the prosecution, grant and maintenance of Patent Rights
regarding (a) Bristol-Myers Inventions, (b) those Joint Inventions that constitute composition of matter and related use inventions (including without limitation Joint Inventions that
constitute Program Antibodies, Products or related Materials necessary solely for the production or use of Program Antibodies or Products or the use of Program Antibodies or Products), and
(c) those Ixsys Inventions that constitute BR96 Antibodies, human or humanized BR96 antibodies, L6 Antibodies, human or humanized L6 antibodies or Products
containing BR96 Antibodies, human or humanized BR96 antibodies, L6 Antibodies, human or humanized L6 antibodies, or related Materials necessary solely for the production or use of any of the foregoing
or the use of Program Antibodies or Products. Ixsys shall control the prosecution, grant and maintenance of Patent Rights regarding all other Joint Inventions and all other Ixsys Inventions. All costs
incurred in connection with the prosecution, grant and maintenance of Patent Rights shall be borne by the party taking action with respect to such Patent Rights. Each party shall inform the other
party at regular intervals, or on request, about the status of patent applications or patents for which it is responsible. 

    In
the event that Ixsys or Bristol-Myers elects not to file a patent application in any country, or decides to abandon any pending application or granted patent in any country,
it shall provide adequate notice to the other party and give the other party the opportunity to file or maintain such application or patent at its own expense; provided,
however, that except for the right to file and maintain such Patent Rights, the rights of Ixsys and Bristol-Myers to such Patent Rights shall not be affected by reason of this
paragraph. 

    14.3  Cooperation.  Each party shall make available to the other party or its authorized attorneys,
agents or representatives, its employees, agents or consultants necessary or appropriate to enable the appropriate party to file, prosecute and maintain patent applications and resulting patents with
respect to Inventions, as set forth in Section 14.2 above, for a period of time sufficient for such party to obtain the assistance it needs from such personnel. Where appropriate, each party
shall sign or cause to have signed all documents relating to said patent applications or patents at no charge to the other. 

    14.4  No Other Technology Rights.  Except as otherwise provided in the Agreement, under no circumstances
shall a party hereto, as a result of the Agreement, obtain any ownership interest or other right in any technology, know-how, patents, pending patent applications, products, vaccines,
antibodies, cell lines or cultures, or animals of the other party, including items owned, controlled or developed by the other, or transferred by the other to such party at any time pursuant to the
Agreement. It is understood and agreed by the parties that the Agreement does not grant to either party any license or other right in basic technology of the other party except to the extent necessary
to enable the parties to carry out their part of the Research Program or the development and marketing of Program Antibodies and Products. 

    14.5  Enforcement of Patent Rights.  (a) Bristol-Myers in the case of (i) all Bristol-Myers
Inventions, (ii) those Joint Inventions that constitute composition of matter and related use inventions (including without limitation Joint Inventions that constitute Program Antibodies,
Products or related Materials necessary solely for the production or use of Program Antibodies or Products or the use of Program Antibodies or Products), and (iii) those Ixsys Inventions that
constitute BR96 Antibodies, human or humanized BR96 antibodies, L6 Antibodies, human or humanized L6 antibodies or Products containing BR96
Antibodies, human or humanized BR96 antibodies, L6 Antibodies, human or humanized L6 antibodies, or related Materials necessary solely for the production or use of any of the foregoing or the use of
Program Antibodies or Products, and (b) Ixsys in the case of all other Joint Inventions and all other Ixsys Inventions, shall have the right but not the obligation to enforce the Patent Rights
against infringers, to control any litigation or other enforcement action and to enter into, or permit, the settlement of any such litigation or other enforcement action with respect to the Patent 

17

Rights, and in good faith shall consider the interests of the other party in so doing. Upon learning of significant and continuing infringement of Patent Rights by a Third Party in the Territory,
Ixsys or Bristol-Myers, as the case may be, promptly shall provide notice to the other party in writing of the fact and shall supply the other party with all evidence possessed by the notifying party
pertaining to and establishing said infringement(s). All monies recovered upon, the final judgment or settlement of any suit regarding Patent Rights shall be retained by the party with the right to
enforce such Patent Rights. Notwithstanding the foregoing, Ixsys and Bristol-Myers shall fully cooperate with each other in any action to enforce the Patent Rights. 

  ARTICLE 15
TERM AND TERMINATION         

    15.1  Expiration.  Unless terminated earlier pursuant to Section 15.2 below, the Agreement shall
expire on the expiration of Bristol-Myers' obligations to pay royalties under the Agreement. 

    15.2  Termination for Cause.  Except as otherwise provided in Article 17, upon the breach of any
material provision of the Agreement, if the breaching party has not cured such breach within ninety (90) days after receipt of written notice thereof from the other party, the Agreement shall
terminate, at the option of the other party, (a) if during the term of the Research Program, on the date which is the earlier to occur of (i) the expiration of the Research Program under
Section 3.5 above, (ii) six (6) months after the expiration of such ninety (90) day cure period if Bristol-Myers is the breaching party, or (iii) on the expiration
of such ninety (90) day cure period if Ixsys is the breaching party, and (b) if after the expiration of the Research Program under Section 3.5 above, on the expiration of such
ninety (90) day cure period. Such termination shall not affect any remedies the nonbreaching party may have at law or in equity. 

    15.3  Effect of Expiration and Termination.  Expiration or termination of the Agreement shall not relieve
the parties of any rights, causes of action or obligations accruing prior to such expiration or termination. The provisions of Sections 6.2 and 21.7 and Articles 12, 13 and 16 shall survive the
expiration or termination of the Agreement, as well as any other provisions necessary to interpret or enforce the Agreement. 

  ARTICLE 16
INDEMNITY         

    16.1  Direct Indemnity.  Each party shall indemnify and hold the other party, its Affiliates and
permitted sublicensees, and their respective directors, officers, employees and agents, harmless, and hereby forever releases and discharges the other party, its Affiliates and permitted sublicensees,
and their respective directors, officers, employees and agents, from and against all claims, demands, liabilities, damages and expenses, including reasonable attorneys' fees and costs (all
"Liabilities"), arising out of negligence, recklessness or intentional acts or omissions of the indemnifying party, its Affiliates or permitted sublicensees, and their respective directors, officers,
employees and agents, in connection with the work performed by such party under the Research Program. Neither Bristol-Myers nor Ixsys shall constitute a sublicensee of the other party for purposes of
this Article 16. 

    16.2  Other Indemnity.  Each party shall indemnify and hold the other party, its Affiliates and permitted
sublicensees, and their respective directors, officers, employees and agents, harmless from and against all Liabilities suffered or incurred in connection with Third Party claims for personal injuries
or any product recall to the extent caused by: (a) any failure to test for or provide adequate warnings of adverse side effects to the extent such failure arises out of acts or omissions in
connection with the preclinical or clinical testing of a Product by such party, its Affiliates and permitted sublicensees, and their respective directors, officers, employees and agents,
(b) any manufacturing 

18

defect in any Product or any other material manufactured by such party, its Affiliates or permitted sublicensees, and their respective directors, officers, employees and agents, or (c) any
other act or omission (without regard to culpable conduct) of such party, its Affiliates or permitted sublicensees, and their respective directors, officers, employees and agents, in making, using or
selling a Product after termination of the Research Program; except in each case to the extent such Liabilities resulted from negligence, recklessness or intentional acts or omissions of the other
party, its Affiliates or permitted sublicensees, and their respective directors, officers, employees and agents. 

    16.3  Procedure.  A party (the "Indemnitee") that intends to claim indemnification under this
Article 16 shall promptly notify the other party (the "Indemnitor") of any Liability or action in respect of which the Indemnitee or any of its Affiliates intend to claim such indemnification,
and the Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so desires, jointly with any other Indemnitor similarly noticed, to assume the defense thereof with counsel
selected by the Indemnitor; provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid
by the Indemnitee, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between such Indemnitee and any
other party represented by such counsel in such proceedings. The indemnity obligations under this Article 16 shall not apply to amounts paid in settlement of any loss, claim, damage, liability
or action if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld unreasonably. The failure to deliver notice to the Indemnitor within a reasonable
time after the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such Indemnitor of any liability to the Indemnitee under this Article 16, but
the omission so to deliver notice to the Indemnitor will not relieve it of any liability that it may have to any Indemnitee otherwise than under this Article 16. The Indemnitee, its employees
and agents, shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action, claim or liability covered by this indemnification. 

    16.4  Insurance.  

      16.4.1  During
the term of the Research Program, Ixsys shall maintain liability insurance, and Bristol-Myers shall maintain a program
of self-insurance, with respect to their respective work performed under the Research Program in such amounts as each customarily maintains with respect to similar research programs, such
protection being applicable to officers, employees, contractors and agents while acting within the scope of their employment or engagement by Ixsys or Bristol-Myers. Ixsys and Bristol-Myers shall
maintain such insurance, or self-insurance program, thereafter for so long as each customarily maintains insurance, or self-insurance programs, for similar research programs. 

      16.4.2  Bristol-Myers
shall maintain, through a program of self-insurance or otherwise, product liability insurance with
respect to development, manufacture and sales of Products, in such amounts as Bristol-Myers customarily maintains with respect to its other products, such protection being applicable to officers,
employees, contractors and agents while acting within the scope of their employment or engagement by Bristol-Myers, Bristol-Myers shall maintain such insurance, or self-insurance program,
thereafter for so long as it customarily maintains insurance, or self-insurance programs, for itself covering such development, manufacture and sales of similar products. 

    16.5  Own Acts.  Each party hereby assumes any and all risks of personal injury or property damage
attributable to the negligent or willful acts or omissions of that party, its Affiliates or permitted sublicensees, and their respective directors, officers, employees and agents. 

19

  ARTICLE 17
FORCE MAJEURE         

    Neither party shall be held liable or responsible to the other party nor be deemed to have defaulted under or breached the Agreement for failure or delay in
fulfilling or performing any term of the Agreement when such failure or delay is caused by or results from causes beyond the reasonable control of the affected party including but not limited to fire,
floods, embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in
acting by any governmental authority or the other party. Any time for performance hereunder shall be extended by the actual time of delay caused by such occurrence. 

  ARTICLE 18
ASSIGNMENT         

    The Agreement may not be assigned or otherwise transferred, nor, except as expressly provided hereunder, may any right or obligations hereunder be assigned or
transferred by either party without the consent of the other party; provided, however, that (a) either Ixsys or Bristol-Myers may, without such
consent, assign the Agreement in its entirety and its rights and obligations hereunder in connection with the transfer or sale of all or substantially all of its business, or in the event of its
merger or consolidation or change in control or similar transaction; and (b) Bristol-Myers may, without such consent, assign the Agreement in its entirety and its rights and obligations
hereunder in connection with the transfer or sale of all or substantially all of its pharmaceutical or oncology business. Any permitted assignee shall assume all obligations of its assignor under the
Agreement. 

  ARTICLE 19
NOTIFICATION OF PATENT TERM RESTORATION         

    Ixsys or Bristol-Myers, as the case may be, shall notify the other party of (a) the issuance of each U.S. patent included within the Patent Rights,
giving the date of issue and patent number for each such patent, and (b) each notice pertaining to any patent included within the Patent Rights which it receives as patent owner pursuant to the
Drug Price Competition and Patent Term Restoration Act of 1984 (hereinafter called the "Act"), including notices pursuant to Paragraphs 101 and 103 of the Act from persons who have filed an
abbreviated NDA ("ANDA"). Such notices shall be given promptly, but in any event within five (5) calendar days of each such patent's date of issue or receipt of each such notice pursuant to the
Act, whichever is applicable. Ixsys or Bristol-Myers, as the case may be, shall notify the other party of each filing for patent term restoration under the Act, any allegations of failure to show due
diligence and all awards of patent term restoration (extensions) with respect to the Patent Rights. Likewise, Ixsys or Bristol-Myers, as the case may be, shall inform the other patty of patent
extensions and periods of data exclusivity in the rest of the world regarding any Product. 

  ARTICLE 20
SEVERABILITY         

    Each party hereby agrees that it does not intend to violate any public policy, statutory or common laws, rules, regulations, treaty or decision of any
government agency or executive body thereof of any country or community or association of countries. Should one or more provisions of the Agreement be or become invalid in any jurisdiction, the
parties hereto shall substitute, by mutual consent, valid provisions for such invalid provisions which valid provisions in their economic effect are sufficiently similar to the invalid provisions that
it can be reasonably assumed that the parties would have entered into the Agreement with such provisions. In case such provisions cannot be agreed upon, the invalidity 

20

of one or several provisions of the Agreement in such jurisdiction shall not affect the validity of the remaining provisions of the Agreement or the Agreement as a whole, or the validity of any of the
terms of the Agreement in any other jurisdiction, unless the invalid provisions are of such essential importance to the Agreement that it is to be reasonably assumed that the parties would not have
entered into the Agreement without the invalid provisions. 

  ARTICLE 21
MISCELLANEOUS         

    21.1  Notices.  Any consent, notice or report required or permitted to be given or made under the
Agreement by one of the parties hereto to the other shall be in writing, delivered personally or by facsimile (and promptly confirmed by personal delivery, U.S. first class mail or courier), U.S.
first class mail or courier, postage prepaid (where applicable), addressed to such other party at its address indicated below, or to such other address as the addressee shall have last furnished in
writing to the addressor and (except as otherwise provided in the Agreement) shall be effective upon receipt by the addressee. 

	If to Ixsys:	 	Ixsys, Inc.

3550 General Atornics Court,

Suite L-103

San Diego, CA 92121

Attention: Michael J. Hanifin
	 

with a copy to:	 
 	 

Pillsbury Madison & Sutro

235 Montgomery Street, 15th Floor

San Francisco, California 94104

Attention: Thomas E. Sparks, Jr.
	 

If to Bristol-Myers:	 
 	 

Bristol-Myers Squibb Company

P.O. Box 4000

Princeton, NJ 08543-4000

Attention: Ronald A. Pepin, Ph.D.
	 

 	 
 	 

 

    21.2  Applicable Law.  The Agreement shall be governed by and construed in accordance with the laws of
the State of California. 

    21.3  Entire Agreement.  The Agreement contains the entire understanding of the parties with respect to
the subject matter thereof. All other express or implied agreements and understandings, either oral or written, heretofore made between the parties with respect to the subject matter hereof, including
without limitation the Prior Agreements, are expressly superseded by the Agreement. The Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by both
parties hereto. 

    21.4  Headings.  The captions to the several Articles and Sections hereof are not an interpretive part of
the Agreement, but are merely guides or labels to assist in locating and reading the several Articles and Sections hereof. The feminine and masculine pronouns are interchangeable hereunder, and the
plural shall be substituted for the singular number in any place in which the context may require such substitution. The Agreement has been prepared jointly and shall not be strictly construed against
either party hereto. 

    21.5  Independent Contractors.  For purposes of the Agreement, and in the performance of all services
hereunder, it is expressly agreed that Ixsys and Bristol-Myers shall be, and shall be deemed to be, independent contractors and that the relationship between the two parties shall not constitute a
partnership, joint venture or agency. Neither Ixsys nor Bristol-Myers shall have the authority to act as 

21

an agent of the other for any purpose, and shall not act on behalf of the other, or make any statements, representations or commitments of any kind, or to take any action, which shall be binding on
the other, without the prior written consent of the other party to do so, or as explicitly provided for herein. 

    21.6  Waiver.  No waiver of any right under the Agreement shall be valid unless made in a written
instrument duly executed by both parties hereto. The waiver by either party hereto of any right hereunder or of the failure to perform or of a breach by the other party shall not be deemed a waiver of
any other right hereunder or of any other breach or failure by said other party whether of a similar nature or otherwise. 

    21.7  No Solicitation of Employees.  During the term of the Research Program and for a period of two
(2) years thereafter, neither Ixsys nor Bristol-Myers nor their respective Affiliates shall, without the prior consent of the other party, solicit the employment of any person who during the
course of employment with 

(THE
BALANCE OF THIS PAGE INTENTIONALLY LEFT BLANK) 

22

the other party or its Affiliate was involved with activities related to the Research Program. 

    21.8  Publicity.  Except as required by applicable law, neither party shall use the name of the other
party, any employee of the other party or any other member of the other party's Research Program staff in any promotion or advertisement, without the prior written consent of the other party. 

    21.9  Counterparts.  The Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. 

    IN
WITNESS WHEREOF, the parties have executed the Agreement as of the date first set forth above. 

	 	 	IXSYS, INC.
	 

 	 
 	 

By:	 
 	 

/s/ MICHAEL J. HANIFIN   
 Michael J. Hanifin
 Vice President, Business Development
	 

 	 
 	 
 BRISTOL-MYERS SQUIBB COMPANY
	 

 	 
 	 

By:	 
 	 

/s/ WILLIAM A. SCOTT   
 William A. Scott
 Senior Vice President

23

QuickLinks

RESEARCH AGREEMENT

ARTICLE 1 DEFINITIONS

ARTICLE 2 REPRESENTATIONS AND WARRANTIES

ARTICLE 3 RESEARCH PROGRAM

ARTICLE 4 DEVELOPMENT AND COMMERCIALIZATION

ARTICLE 5 MANAGEMENT OF THE RESEARCH PROGRAM

ARTICLE 6 GRANT OF LICENSES

ROYALTIES AND MILESTONE PAYMENTS

ARTICLE 8 ROYALTY REPORTS AND ACCOUNTING

ARTICLE 9 PAYMENTS

ARTICLE 10 [INTENTIONALLY OMITTED]

ARTICLE 11 INFRINGEMENT ACTIONS BY THIRD PARTIES

ARTICLE 12 CONFIDENTIALITY

ARTICLE 13 PUBLICATION

ARTICLE 14 PATENTS

ARTICLE 15 TERM AND TERMINATION

ARTICLE 16 INDEMNITY

ARTICLE 17 FORCE MAJEURE

ARTICLE 18 ASSIGNMENT

ARTICLE 19 NOTIFICATION OF PATENT TERM RESTORATION

ARTICLE 20 SEVERABILITY

ARTICLE 21 MISCELLANEOUS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}]]